Clinical Trails

The PREP-02/JSAP05 trial showed that giving chemotherapy before surgery can improve survival for patients with Pancreatic Ductal Adenocarcinoma, the most common type of pancreatic cancer. In this study, researchers compared two treatment approaches. One group of patients had immediate surgery, while the other received chemotherapy with Gemcitabine and S-1 before surgery. After surgery, both groups […]

Can-Fite BioPharma announced that its Phase 2a trial of namodenoson (CF102) met its primary safety goal in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC). The study included 20 heavily pretreated patients whose disease had progressed after prior therapies. Namodenoson was well tolerated, with no new safety concerns, and its safety profile was consistent with previous

Results from the Phase 3 BREAKWATER trial suggest a new first-line treatment approach for metastatic colorectal cancer with the BRAF V600E mutation. Using targeted therapy early can significantly improve outcomes for patients with this aggressive form of cancer. The treatment combines encorafenib (Braftovi), cetuximab (Erbitux), and fluorouracil-based chemotherapy. In the trial, the combination achieved an

The Phase 3 KEYNOTE-B96 study shows that adding Pembrolizumab (Keytruda) to weekly paclitaxel, with or without bevacizumab, helps patients with platinum-resistant ovarian cancer live longer. This is the first immune checkpoint inhibitor regimen to significantly improve overall survival in this setting. Patients who received the combination lived a median of 17.7 months compared with 14.0

Immunotherapy has greatly improved treatment for advanced melanoma, but liver metastases remain a major challenge. The liver can act as an “immune sink,” where special immune cells destroy the T cells that are supposed to fight cancer. This weakens the body’s overall immune response and makes liver tumors especially hard to treat. In the CHOPIN

Researchers found that ovarian cancer cells quickly turn on a “pro-survival program” soon after treatment with PARP inhibitors begins. This fast response helps explain why these drugs can stop working, even if they seem effective at first. The team identified a protein called FRA1 as the key driver of this early resistance, allowing cancer cells

Researchers have developed a new nanomaterial that destroys cancer cells by triggering a dual chemical attack inside tumors. The study, published in Advanced Functional Materials, improves chemodynamic therapy (CDT). Unlike traditional CDT agents that produce only one harmful molecule, this iron-based material generates both hydroxyl radicals and singlet oxygen. These highly reactive molecules damage DNA

Results from the phase 2 CYTOSHRINK trial show that adding Stereotactic Body Radiation Therapy (SBRT) to the immunotherapy combination of nivolumab and ipilimumab does not improve outcomes for patients with newly diagnosed advanced renal cell carcinoma (RCC). In fact, progression-free survival was shorter in the SBRT group (6.3 months) compared with immunotherapy alone (10.2 months).

Results from the LITESPARK-011 Phase 3 trial show that the combination of belzutifan (Welireg) and lenvatinib (Lenvima) is more effective than cabozantinib (Cabometyx) for patients with advanced clear cell renal cell carcinoma (ccRCC) previously treated with immunotherapy. The combination improved progression-free survival to 14.8 months compared with 10.7 months for cabozantinib, reducing the risk of disease progression or

Prostate cancer treatment has evolved from general hormone therapy to a personalized “ABCs + D” approach. While localized prostate cancer has a high 5-year survival rate, the focus is now on metastatic castration-resistant prostate cancer (mCRPC), which has historically had poor outcomes. Modern care emphasizes intensifying treatment earlier to achieve deeper responses. The “ABCs +